The text starts here.

News Release

June 9, 2005

Eisai Announces Establishment of its Pharmaceuticals Marketing Subsidiary in Switzerland

Eisai Co., Ltd. (Headquarters: Tokyo, President: Haruo Naito) announced that on June 6, 2005, it established a pharmaceuticals marketing subsidiary, Eisai Pharma AG in Switzerland. Eisai Pharma AG is owned by Eisai Europe Limited (Headquarters: London, President: Yutaka Tsuchiya).

In Switzerland, Eisai Pharma AG plans to sell and promote pharmaceuticals mainly in the neurology area and the marketing applications for the anti-epileptic drugs ZonegranR and InovelonR will be submitted in Switzerland in the future. The newly established subsidiary company will also promote active business development, and aims at establishing an efficient and profitable business framework.

Eisai already has marketing subsidiaries in the U.K., France, Germany, Spain and Italy. The company also holds branch offices of the UK and German subsidiaries in Ireland and Austria, respectively. The company aims at expanding its sales network rapidly for its own products in European countries.

Switzerland has a highly developed medical system and its pharmaceutical market is expected to grow steadily in the future. Eisai Pharma AG will provide a stable supply of high quality products and appropriate product information for safe and proper usage to meet the medical needs of patients in Switzerland.

[Company Outline]
Company Name :Eisai Pharma AG
Capital :3 million Swiss Fran (approx. 260 million yen)
Location :Zurich, Switzerland
Operations :Promotion/sale of pharmaceuticals


Eisai Co., Ltd.
Corporate Communications Department
Phone 03-3817-5120 (Tokyo)